The aim of this proposal is to test the safety of a novel immunotherapy based on Helicobacter pylori platform technology to treat childhood allergies. Repeated oral administration of killed H. pylori mimics colonisation in the stomach and assists the development of a balanced immune system without the associated disease risk of live H. pylori. To achieve this goal Professor Barry Marshall has assembled a cross-disciplinary team of experts from Industry, Academia and Clinic.
From The Synchrotron To The Clinic: Translation Of A Novel Functional Lung Imaging Technology
Funder
National Health and Medical Research Council
Funding Amount
$891,834.00
Summary
Our team has recently developed a synchrotron technology with a startling capacity for dynamic functional imaging that can act as a sensitive regional indicator of lung disease. We will demonstrate that this technology can be translated from the synchrotron to the lab and eventually the clinic. We will provide proof of this concept by the application of this technology to emphysema, asthma, lung cancer, cystic fibrosis lung disease and neonatal resuscitation.